A Pharmacodynamic Study Using NaF PET/CT Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Metastatic Castrate Resistant Prostate Cancer to Bone
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2018
Price : $35 *
At a glance
- Drugs Orteronel (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 20 Jul 2017 Status changed from active, no longer recruiting to discontinued because Study supporter (Takeda) ended study drug for prostate cancer; enrollment ended prematurely.
- 17 Jun 2016 Planned End Date changed from 1 May 2016 to 1 Dec 2016.